ZVSA

0.00010.00%
JR

James R. Sapirstein

Independent Director

Mr. James R. Sapirstein is Independent Director of INmune Bio Inc. from September 8, 2026. He is Chief Executive Officer of Cocrystal Pharma, Inc. from June 3, 2026. He is currently the Chairman and Chief Executive Officer of 8 Prime Biosciences and has been an Independent Director of ZyVersa Therapeutics, Inc. since January 2023. He served as Executive Chairman of Onconetix, Inc. (formerly known as Blue Water Biotech, Inc. and Blue Water Vaccines, Inc.) from February 24, 2025, until March 28, 2025 and as its Independent Non-Executive Director from February 23, 2022, until March 28, 2025. Mr. Sapirstein was Non-Executive Chairman and Lead Independent Director of Onconetix, Inc. from October 2023 until February 24, 2025 and Interim Executive Chairman from September 30, 2023, until October 2023. He served as Chairman and CEO of Entero Therapeutics (ENTO:NASDAQ) from October 2019 until February 2025 and as Chief Executive Officer of ContraVir Pharmaceuticals (now Hepion Pharmaceuticals, Inc.) from March 2014 until October 2018. Mr. Sapirstein was Chief Executive Officer and Director of Entero Therapeutics, Inc. from October 8, 2019 and Chairman of the Board from February 19, 2021, until February 2025. He served as President at Entero Therapeutics, Inc. from October 8, 2019, until March 2024. He served as Interim Chief Executive Officer at Marizyme, Inc. from March 19, 2021, until June 24, 2021 and as Executive Chairman and Director of Marizyme Incorporated from December 10, 2018, until June 24, 2021, as well as Interim Chief Executive Officer from September 1, 2020, until November 1, 2020. Mr. Sapirstein served as Independent Director of Renovaro Inc. (formerly Enochian Biosciences Inc.) from March 2018 until October 12, 2024, Independent Director of NanoViricides, Inc. from November 1, 2018, until February 10, 2020 and Chief Executive Officer of Hepion Pharmaceuticals, Inc. until October 3, 2018. He served as Director of Hepion Pharmaceuticals, Inc. since March 19, 2014 and as Executive Vice Chairman of the Board at RespireRx Pharmaceuticals Inc. from December 28, 2018, until December 20, 2019 and as Director from September 03, 2014, until December 20, 2019. He has served as Director of Leading BioSciences Inc. since March 2016 and as Independent Director of Cortex Pharmaceuticals, Inc. since September 2014. He also serves as Independent Non-Executive Director at Blue Water Acquisition Corp. since December 2020 and was Director of BWAC from December 2020 until September 2021. Mr. Sapirstein served as Strategic Advisor of Muscle Pharm Corp., Strategic Advisor of Tobira Therapeutics, Inc. and Strategic Advisor of HIV/AIDS Market for Therapeutic Nutritional Products at Muscle Pharm Corp. since February 2011. He served as Chief Executive Officer of Alliqua Biomedical, Inc./Alliqua Therapeutics from October 2012 to February 2014, as President from November 2012 to February 2013 and as Director from October 1, 2012, to February 2013. He founded and served as Chief Executive Officer of Tobira Therapeutics from October 2006 to April 2011 and as President from August 2007 to April 4, 2011. Mr. Sapirstein served as Executive Vice President, Metabolic and Endocrinology for Serono Laboratories from June 2002 to May 2005. He launched several HIV/AIDS agents worldwide in the biotechnology and pharmaceutical industry. He served as Head of International HIV business and Director of International Marketing of the Infectious Disease Division at Bristol-Myers Squibb from July 1996 to June 2000 and led the global marketing strategy for Gilead’s flagship HIV drug Viread, playing an instrumental role in the development of the drug combination strategy that resulted in Gilead’s acquisition of Triangle’s nucleoside portfolio. Mr. Sapirstein’s earlier career included several senior-level positions in marketing and commercialization, including as Global Marketing Lead for Viread (tenofovir) at Gilead Sciences from June 2000 to June 2002. He began his career in 1984 with Eli Lilly and accepted a position at Hoffmann-LaRoche in 1987, serving for almost a decade as part of its commercial teams in the US and abroad. He is a Director for Biotechnology Innovation Organization (BIO), Chairman Emeritus of BIO New Jersey Chapter (BioNJ) and sits on both the Health Section Governing Board and Emerging Companies Section Governing Board. He served as Chair Emeritus of BioNJ Inc. from February 9, 2017, to February 2019 and Trustee since April 29, 2015. He was named as a Finalist for the Ernst & Young Entrepreneur of the Year award in 2015 and 2016. Mr. Sapirstein has raised over 600 million in venture capital and public capital markets financing in his various engagements as Chief Executive Officer. He serves as Advisory Board Director at the Fairleigh Dickinson School of Pharmacy, Member of the Board of Directors of Clinical Supplies Management, Inc. and as a Member of the Advisory Board at MusclePharm Corp. He served as Director at Probility Media Corporation (Panther Biotechnology, Inc.) since May 20, 2014 and its Scientific Advisory Board Member since November 7, 2016. He served as Director of BIO’s Emerging Company Board. Mr. Sapirstein received an MBA in Management from Fairleigh Dickinson University in 1997 and earned a B.S. in Pharmacy from Rutgers University in 1984.

Positions